LBRX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nov 5, 2026

8-K

LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer

Sep 15, 2026

8-K

LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer

Sep 3, 2026

8-K

LB Pharmaceuticals Reports Q2 2026 Financial Results and Accelerates Phase 3 Data Timeline

Aug 11, 2026

8-K

LB Pharmaceuticals Announces $150 Million Private Placement

Jul 29, 2026

8-K

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia

Jul 22, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Sep 15, 2026

424B3

UPDATE TO PRIOR PROSPECTUS

Sep 3, 2026

424B3

UPDATE TO PRIOR PROSPECTUS

Aug 11, 2026

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Jul 29, 2026

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Jul 22, 2026

424B3

OFFERING - OTHER

Jun 10, 2026

Registrations

TYPE

HEADLINE

FILED AT

POS AM

SHARE RESALE REGISTRATION | Shares: 4,778,491 EFFECTIVE, DATED 2026-10-05

Oct 1, 2026

S-3ASR

October 2026 SHELF + ATM + SHARE RESALE REGISTRATION

Oct 1, 2026

S-1

SHARE RESALE REGISTRATION | Shares: 4,778,491

Apr 6, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 26, 2026

S-1MEF

SHARE RESALE REGISTRATION | | Offering amount: $21,083,328

Sep 10, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Sep 10, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2026

Ownerships

TYPE

HEADLINE

FILED AT

Miller Joseph M (Reporting)

Oct 13, 2026

Kozauer Susan Gani (Reporting)

Oct 13, 2026

SCHEDULE 13G/A

JPMORGAN CHASE & CO (Filed by)

Oct 13, 2026

Kozauer Susan Gani (Reporting)

Sep 24, 2026

Miller Joseph M (Reporting)

Sep 14, 2026

SCHEDULE 13G/A

TCG Crossover GP II, LLC (Filed by)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 6, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 15, 2026

CORRESP

Form CORRESP - Correspondence

Apr 10, 2026

LETTER

Form UPLOAD - SEC-generated letter

Apr 10, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 11, 2025

CORRESP

Form CORRESP - Correspondence

Sep 9, 2025

LB Pharmaceuticals Inc Common Stock LBRX · SEC Filings